Optimizing Clinical Development: Saving Time and Costs Blog Post
Strategic Mechanisticモデリングソリューションは、免疫療法のバイオテクノロジー企業が新規治療法の臨床開発を加速させるのに役立ちます。
Certara Launches Phoenix™ Version 8.5 Drug Development Software Blog Post
RADNOR, PA – 2024年8月15日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical…
Certara Research Reveals IRA’s Impact on Biosimilar Uptake Blog Post
RADNOR, PA – 2024年8月15日 — Certara, Inc., a global leader in model-informed drug development, has published new research on the impact of the Inflation Reduction Act (IRA) on…
Medicines that matter: Biohaven’s Nurtec™ drug development journey Blog Post
In February 2020, Biohaven Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved Nurtec™ (Rimegepant) for the acute treatment of migraines in adults. In May 2021 the FDA...
All you need to know about NCI, CDISC and SDTM controlled terminology Blog Post
The use of controlled terminology (CT) is vital to successful clinical study build. In clinical trials, CT can be referred to in several different ways, such as: While these terms…
Model-Informed Confidence in Oncology Dose Selection Blog Post
Discover an oncology-focused company that gained confidence in their dose selection for an AML trial with pediatric patients and reduced their clinical development costs, by using mechanistic modeling. Sutro is...
Pinnacle 21 Enterprise: Dataset Validation & Submission Readiness Blog Post
Pinnacle 21 Enterpriseがどのようにデータセットのバリデーション簡素化、コンプライアンス強化し、規制当局への提出書類準備をサポートするのか説明しています。
Digital Payer Portals for Enhanced Value Communication Blog Post
The trend of using digital tools for communication and information sharing in the life science industry has gained traction. Market access professionals work differently today. This shift began over the…
